Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes
- PMID: 22294344
- PMCID: PMC3474541
- DOI: 10.1002/art.34409
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes
Abstract
Objective: Blocking interleukin-1 with anakinra in patients with the autoinflammatory syndrome neonatal-onset multisystem inflammatory disease (NOMID) reduces systemic and organ-specific inflammation. However, the impact of long-term treatment has not been established. This study was undertaken to evaluate the long-term effect of anakinra on clinical and laboratory outcomes and safety in patients with NOMID.
Methods: We conducted a cohort study of 26 NOMID patients ages 0.80-42.17 years who were followed up at the NIH and treated with anakinra 1-5 mg/kg/day for at least 36 months. Disease activity was assessed using daily diaries, questionnaires, and C-reactive protein level. Central nervous system (CNS) inflammation, hearing, vision, and safety were evaluated.
Results: Sustained improvements in diary scores, parent's/patient's and physician's global scores of disease activity, parent's/patient's pain scores, and inflammatory markers were observed (all P<0.001 at 36 and 60 months). At 36 and 60 months, CNS inflammation was suppressed, with decreased cerebrospinal fluid white blood cell counts (P=0.0026 and P=0.0076, respectively), albumin levels, and opening pressures (P=0.0012 and P<0.001, respectively). Most patients showed stable or improved hearing. Cochlear enhancement on magnetic resonance imaging correlated with continued hearing loss. Visual acuity and peripheral vision were stable. Low optic nerve size correlated with poor visual field. Bony lesions progressed. Adverse events other than viral infections were rare, and all patients continued to receive the medication.
Conclusion: These findings indicate that anakinra provides sustained efficacy in the treatment of NOMID for up to 5 years, with the requirement of dose escalation. Damage progression in the CNS, ear, and eye, but not bone, is preventable. Anakinra is well tolerated overall.
Trial registration: ClinicalTrials.gov NCT00069329.
Copyright © 2012 by the American College of Rheumatology.
Figures
Similar articles
-
Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.Arthritis Rheum. 2010 Jan;62(1):258-67. doi: 10.1002/art.25057. Arthritis Rheum. 2010. PMID: 20039428
-
Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.Arthritis Rheumatol. 2017 Jun;69(6):1325-1336. doi: 10.1002/art.40055. Epub 2017 May 10. Arthritis Rheumatol. 2017. PMID: 28118536 Free PMC article.
-
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.Rheumatology (Oxford). 2016 Aug;55(8):1499-506. doi: 10.1093/rheumatology/kew208. Epub 2016 May 3. Rheumatology (Oxford). 2016. PMID: 27143789 Free PMC article. Clinical Trial.
-
Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.Curr Rheumatol Rep. 2011 Apr;13(2):123-31. doi: 10.1007/s11926-011-0165-y. Curr Rheumatol Rep. 2011. PMID: 21538043 Free PMC article. Review.
-
Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature.J Otolaryngol Head Neck Surg. 2018 Jan 30;47(1):9. doi: 10.1186/s40463-018-0256-0. J Otolaryngol Head Neck Surg. 2018. PMID: 29382382 Free PMC article. Review.
Cited by
-
Fetal origin of bronchopulmonary dysplasia: contribution of intrauterine inflammation.Mol Med. 2024 Sep 3;30(1):135. doi: 10.1186/s10020-024-00909-5. Mol Med. 2024. PMID: 39227783 Free PMC article. Review.
-
Updates on Genetic Hearing Loss: From Diagnosis to Targeted Therapies.J Audiol Otol. 2024 Apr;28(2):88-92. doi: 10.7874/jao.2024.00157. Epub 2024 Apr 10. J Audiol Otol. 2024. PMID: 38695053 Free PMC article.
-
Case report: Novel compound heterozygous IL1RN mutations as the likely cause of a lethal form of deficiency of interleukin-1 receptor antagonist.Front Immunol. 2024 Apr 5;15:1381447. doi: 10.3389/fimmu.2024.1381447. eCollection 2024. Front Immunol. 2024. PMID: 38646532 Free PMC article.
-
Clinical and Genetic Spectrum of Nine Cases of NLRP3-Associated Autoinflammatory Disease (NLRP3-AID) and Identification of One Novel NLRP3 Mutation by Genetic Variation Analyses.J Immunol Res. 2024 Mar 6;2024:5722548. doi: 10.1155/2024/5722548. eCollection 2024. J Immunol Res. 2024. PMID: 38481988 Free PMC article.
-
Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA).Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20. Paediatr Drugs. 2024. PMID: 38376736
References
-
- Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203–17. - PubMed
-
- Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA) Pediatr Radiol. 2007;37:145–52. - PubMed
-
- Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome: a specific entity analysed in 30 patients. Scand J Rheumatol Suppl. 1987;66:57–68. - PubMed
-
- Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated auto-inflammatory diseases. Arthritis Rheum. 2002;46:3340–8. - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials